Editorial: New drugs in lipid lowering therapy

Rogożik and co-authors present a compelling case report of a patient with familial hypercholesterolemia (FH) who could not tolerate statins and did not respond to ezetimibe or alirocumab 6. Their LDL-C levels fell significantly only after starting inclisiran, a small interfering RNA-based treatment. This case illustrates the value of multiple therapeutic options what fails for one patient may be transformative for another. Inclisiran's twice-yearly dosing may also improve adherence for patients who struggle with daily pills or more frequent injections 7.Adding another layer to the discussion, Liu et al. used Mendelian randomization (MR) to explore the genetic impact of LLTs on uric acid and gout 8. Interestingly, their findings suggest that while statins might slightly increase gout risk, PCSK9 inhibition could modestly raise urate levels. This has no immediate clinical implications, but the study reminds us to monitor for potential adverse effects to improve therapy adherence 9.Meanwhile, Langhi and colleagues take a different approach by studying Totum-070, a polyphenol-rich plant extract, in a mouse model 10. Their work showed improvements not only in cholesterol levels but also in gut microbiota composition and markers of metabolic health. While still early-stage, this research points to potentially gentler ways (with diet enrichment) to address dyslipidemia, perhaps as adjuncts or alternatives for some patients 11.Marcinkowska and colleagues add another dimension by investigating lipid biomarkers through a machine learning approach. Studying 162 patients with premature coronary artery disease, they found that elevated lipoprotein(a) Lp(a) and LDL-C levels were associated with greater coronary lesion complexity, as assessed by the SYNTAX score. An Lp(a) cut-off of 63.5 mg/dL discriminated patients with complex coronary disease (AUC 0.620), and a multivariate linear discriminant analysis model combining Lp(a), LDL-C, age, and sex achieved strong predictive accuracy (AUC 0.800) 12. Hu et al. present a network meta-analysis showing that emerging Lp(a)-targeted therapies can achieve profound reductions in Lp(a), with all evaluated agents producing substantial lowering compared with placebo. siRNA-based therapies, particularly olpasiran and zerlasiran, demonstrated the most pronounced effects, with olpasiran achieving the greatest absolute and percentage reductions. These therapies were also associated with modest improvements in LDL-C and apoB, suggesting broader benefits on atherogenic lipoprotein burden. Overall safety appeared favorable, although injection-site reactions were more frequent with some agents, underscoring the need for confirmation of long-term clinical outcomes in ongoing trials 13.Together, these articles reflect the diversity of strategies now being explored in LLT. Whether via monoclonal antibodies, siRNA-based treatments, or plant-derived compounds, the goal is the same: reduce CVD risk by targeting lipids more effectively and, ideally, more safely. It is encouraging that the field is moving toward more personalized approaches matching the right therapy to the right patient at the right time 14.Cost-effectiveness remains a topic of debate, particularly in public health systems. And while safety profiles are generally reassuring, long-term data are still needed for many of these therapies. We are in an exciting phase of discovery, but with that comes the responsibility to keep asking rigorous questions about value, access, and long-term outcomes. This collection of articles reflects a moment of real progress in CVD prevention. As clinicians and researchers, we are better equipped than ever to help patients manage their lipid levels and ultimately their risk of heart disease. Yet these new tools require careful judgment and ongoing learning. The future is promising, and these contributions help us take the next step forward.